Venus Remedies expands ASEAN presence with new drug approvals in Vietnam
Venus Remedies now has 29 active product approvals in Vietnam alone
Venus Remedies now has 29 active product approvals in Vietnam alone
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis
Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain
The upcoming state-of-the art 400+ bed facility is set to come up at an approximate cost of Rs 500 crore
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
Subscribe To Our Newsletter & Stay Updated